EXPLORING THE THERAPEUTIC POTENTIAL OF ROSUVASTATIN IN WOUND HEALING: A MOLECULAR DOCKING PERSPECTIVE

Dhilip S., Dr. Pandian C.* and Dr. Abdul Hasan Sathali A.

ABSTRACT

Rosuvastatin, a synthetic HMG-CoA reductase inhibitor, has been shown in experiments to be beneficial in wound healing because it reverses the action of wound healing inhibitors like farnesyl pyrophosphate (FPP) and increases microvascular and endothelial activity, thereby improving wound healing processes. The work used molecular docking to analyze the interactions between rosuvastatin and nine wound healing-associated proteins (FGFR1, TGFR-β 1, VEGFR2 & 3, MMP9 & 12, ERB-β1, PDGFR, and RAGE). The molecular docking simulations were run with PyRx software, which predicted the binding relationships between rosuvastatin and the target proteins. Rosuvastatin's binding energies with each protein were computed to establish their affinity for the ligand. The docking studies showed that rosuvastatin had favourable binding interactions with all nine proteins, indicating that it has the ability to modulate their activity. MMP 9 proteins had the greatest binding energy among the target proteins, followed by TGFR-β1, ERB-β1, MMP-12, VEGFR 2, PDGFR, VEGFR 3, RAGE, and FGFR 1 in decreasing order of binding energies. In this study, we looked at the impact of Rosuvastatin (RSV) on nine proteins linked with poor wound healing. These nine proteins are linked and contribute to poor wound healing. The effect of RSV on these proteins was established utilizing molecular docking experiments. The PyRx application was used to conduct docking simulations between RC and the nine proteins related to poor wound healing. Visualizing the binding connections between rosuvastatin and the target proteins revealed molecular interactions and probable mechanisms of action. The findings highlight the rosuvastatin's therapeutic potential in targeting particular proteins involved in wound healing impairment, establishing it as a viable treatment for chronic wounds.

Keywords: Rosuvastatin, molecular docking, wound healing FGFR1, TGFR-? 1,VEGFR2 & 3 , MMP9 & 12, ERB-?1, PDGFR and RAGE.